Morgan Stanley’s ProShares UltraShort Health Care RXD Stock Holding History

Morgan Stanley’s Portfolio RXD Stock Details RXD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2	Closed	-$31	–	8556
2026 Q1	$31	Buy	2 +1	+100%	+$18	﹤0.01%	8097
2025 Q4	$22	Sell	1 -1	-50%	-$20	﹤0.01%	8068
2025 Q3	$35	Hold	2	–	–	﹤0.01%	7952
2025 Q2	$40	Hold	2	–	–	﹤0.01%	7855
2025 Q1	$45	Buy	2 +1	+100%	+$22	﹤0.01%	7755
2024 Q4	$21	Hold	1	–	–	﹤0.01%	7864
2024 Q3	$13	Hold	1	–	–	﹤0.01%	7850
2024 Q2	$17	Hold	1	–	–	﹤0.01%	7751
2024 Q1	$10	Buy	+1	New	+$22	﹤0.01%	7767

Other funds holding RXD

IMC Chicago Chicago, Illinois $419B AUM 72.04% 1-Year Est. Return

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley's RXD Position: Q2 2026 in Review

Morgan Stanley sold out of ProShares UltraShort Health Care (RXD) in Q2 2026, closing a stake of 2 shares — an estimated $31 sold.

Morgan Stanley first reported a position in RXD in Q1 2024 and held it in 9 quarters. The position peaked at $45 in Q1 2025. 3 funds tracked by Wall St. Rank hold RXD as of Q2 2026.

Morgan Stanley reported no remaining ProShares UltraShort Health Care position as of Q2 2026 after selling out during the quarter.
Morgan Stanley sold 2 ProShares UltraShort Health Care shares in Q2 2026, an estimated $31.
Morgan Stanley first reported a position in ProShares UltraShort Health Care in Q1 2024 and held it in 9 quarters.
Morgan Stanley's ProShares UltraShort Health Care position peaked at $45 in Q1 2025.
3 funds tracked by Wall St. Rank held ProShares UltraShort Health Care as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.